AtaiBeckley names Michael Faerm as finance chief

Core Viewpoint - AtaiBeckley NV has appointed Michael Faerm as chief financial officer, effective March 9, 2026, to enhance its financial strategy as it advances its mental health treatment pipeline [1]. Group 1: Appointment Details - Michael Faerm brings over 25 years of experience in life sciences, equity research, and investment banking [1]. - Faerm's previous roles include CFO at Viracta Therapeutics and interim CFO at Harpoon Therapeutics, which was acquired by Merck [2]. - He has also held positions at Innoviva, Forest Laboratories, and Regeneron Pharmaceuticals, focusing on business development and strategic finance [2]. Group 2: Financial Strategy and Leadership Transition - Faerm will oversee the company's financial strategy, capital markets activities, and overall financial operations [1]. - Current CFO Anne Johnson will transition to chief accounting officer, continuing to lead accounting and financial operations while supporting Faerm [3]. - The CEO of AtaiBeckley, Srinivas Rao, emphasized the importance of Faerm's strategic finance background as the company advances its lead candidate BPL-003 toward Phase 3 [4]. Group 3: Future Outlook - Faerm expressed enthusiasm about joining AtaiBeckley at a pivotal time, with BPL-003 advancing and a strong clinical-stage pipeline [5]. - He looks forward to collaborating with Johnson and the leadership team to support the company's late-stage development [6].